( September 30, 2026, 19:04 GMT | Official Statement) -- MLex Summary: Sage Chemical and TruPharma filed a reply in support of their motion for judgment in a US case accusing Supernus Pharmaceuticals, Britannia Pharmaceuticals, and US WorldMeds Partners of engaging in a conspiracy to restrain generic competition for branded Apokyn. They argued that the companies failed to contradict the direct effects of their scheme: a 1,795 percent price increase, reduced output of the 5,000 injectable pens offered to Sage and TruPharma, and canceled generic cartridge purchases. Additionally, they do not rebut the authorities or evidence that the alleged restraints were not reasonably necessary to achieve their asserted justifications.See attached file....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.